Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 3 1Phase 1 1

Status

Completed 50Terminated 6Unknown 5Active not recruiting 2No longer available 1

Sponsor Class

OTHER 2INDUSTRY 2OTHER_GOV 1NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Prostatic Neoplasms 36Lymphoma, Large B-Cell, Diffuse 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 7Neoplasms 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Leukemia 6Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 3Neoplasm Metastasis 3Lymphoma, T-Cell 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Pain 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Hematologic Diseases 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumours 1Sezary Syndrome 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Prednisone × Clear all
NCT04083898 2024-03-19

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Washington University School of Medicine

Phase 1 Terminated
15 enrolled
Plasma cell

Multiple Myeloma

NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02773550 2020-01-18

Velcadito

Basque Health Service

Phase 4 Terminated
24 enrolled
Plasma cell

Multiple Myeloma

NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
442 enrolled 17 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT00644306 2008-03-26

IFM 01/01

Central Hospital, Nancy, France

Phase 3 Terminated
232 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡